BrightPath Biotherapeutics Co., Ltd.
4594.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥0 | ¥0 | ¥1 | ¥0 |
| % Growth | -100% | -96.8% | 3,063.6% | – |
| Cost of Goods Sold | ¥0 | ¥0 | ¥0 | ¥0 |
| Gross Profit | ¥0 | ¥0 | ¥1 | ¥0 |
| % Margin | – | 75.8% | 99% | 75.8% |
| R&D Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥219 | ¥245 | ¥346 | ¥273 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥219 | ¥245 | ¥346 | ¥273 |
| Operating Income | -¥219 | -¥245 | -¥345 | -¥273 |
| % Margin | – | -743,484.8% | -33,067% | -827,693.9% |
| Other Income/Exp. Net | -¥1 | ¥4 | ¥10 | -¥3 |
| Pre-Tax Income | -¥220 | -¥241 | -¥336 | -¥276 |
| Tax Expense | ¥1 | ¥1 | ¥0 | ¥0 |
| Net Income | -¥221 | -¥242 | -¥336 | -¥276 |
| % Margin | – | -732,936.4% | -32,190% | -837,421.2% |
| EPS | -1.98 | -2.59 | -3.82 | -3.19 |
| % Growth | 23.6% | 32.2% | -19.7% | – |
| EPS Diluted | -1.98 | -2.59 | -3.82 | -3.19 |
| Weighted Avg Shares Out | 111 | 93 | 88 | 87 |
| Weighted Avg Shares Out Dil | 111 | 93 | 88 | 87 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥0 | ¥0 | ¥0 | ¥0 |
| Depreciation & Amortization | ¥0 | ¥0 | ¥0 | ¥0 |
| EBITDA | -¥220 | -¥241 | -¥336 | -¥276 |
| % Margin | – | -731,103% | -32,144.5% | -835,978.8% |